Overview

Abstract (English)

The use of second-generation antipsychotic (SGA) has increased substantially in Canada over the last decade. Though an association has been found between SGAs and metabolic dysfunction in randomized controlled trials (RCTs), this information might not be generalizable to all SGA users. Furthermore, SGA use has been inadequately characterized in the population. This thesis aimed to quantify trends in SGA use and the effect of SGAs on indicators of metabolic dysfunction in the Canadian population through two studies: i) a systematic review the literature on population-based studies of SGA use and their associated metabolic harms, and ii) a cross-sectional analysis of SGA use using the Canadian Health Measures Survey (CHMS). The results of this thesis showed SGA use has tripled in Canada between 2007 and 2013 and confirmed the presence of metabolic dysfunction and poor health in SGA users in the general household population.

Abstract (French)

Please note that abstracts only appear in the language of the publication and might not have a translation.